its unique mechanism of action, distinct response patterns were observed and considered to be efficacy of the drug. Approximately 30% of patients treated with ipilimumab had disease control according to traditional RECIST criteria. They either had complete, partial response or stable disease. Some patients initially showed stable disease and then showed a decrease in tumor mass. The most interesting finding was that there was an initial increase in tumor mass and/or appearance of new lesions followed by decrease in the tumor mass or the tumor stopped growing further (stable disease). [3] Ipilimumab not only revised the way response is evaluated, but also showed unique emergent side effects because of its unique mechanism of action. The new set of guidelines named as immune-related adverse events (irAEs) was introduced. These side effects included hypophysitis, colitis, hepatitis, pneumonitis, and rash. There are increasing case reports of patients who develop irAEs resembling inflammatory and rheumatic diseases such as arthritis, nephritis, myositis, and polymyalgia-like syndromes, and even type I diabetes in adults. [4] No wonder that such a landmark drug had many twists in the patents which made it one of the most twisted affairs. The University of California, Berkeley, had experience to take the research and patents till preclinical stage only, but they patented clinical application of the invention in 1995 and moved ahead with licensing it out to a small company NeXstar Pharmaceuticals, which later on got merged with the biopharmaceutical company, Gilead Sciences Inc. Gilead sublicensed the rights to Medarex in 1999. Bristol-Myers Squibb (BMS) acquired Medarex in 2009. But, during this period, Medarex and Pfizer had signed an agreement in 2004 for co-development in spite of the fact that Pfizer was already into the development of its own anti-CTLA CP-675,206 (later named as tremelimumab). However, this collaboration lasted for a short duration, and finally, the product landed with BMS in 2005, who developed it further till commercialization. BMS had patented CTLA as a stimulator of T-cells and this prevented Dr. Allison to find a suitable developer for this drug before Medarex stepped in, as the patent position of this drug was considered "dirty" by potential investors.
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Letter to the Editor Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer DOI: 10.4103/sajc.sajc_199_18
Dear Editor, Alectinib is a highly selective, potent inhibitor of anaplastic lymphoma kinase (ALK). Phase 2 data suggest that alectinib elicits response in 46% with crizotinib-resistant disease, [1] making it a better alternative to chemotherapy. We describe a case of crizotinib-resistant ALK + non-small-cell lung cancer (NSCLC) and our experience with alectinib as third-line tyrosine kinase inhibitor (TKI) therapy.
A 47 year-old female was evaluated for cough in September 2014. Supraclavicular node biopsy confirmed lung cancer of adenosquamous histology and ALK was amplified on fluorescence in situ hybridization. Positron emission tomography-computed tomography (CT) and magnetic resonance imaging brain showed right-lobe lung lesion, nodal metastasis, and brain metastasis. She was started on crizotinib in October 2014. She had clinical and radiological response sustained until December 2015. Serial CT scan done thereafter showed gradual radiological progression at single disease site. Crizotinib was continued as she remained asymptomatic. In July 2016, ceritinib was started in view of a significant increase in radiological burden of disease.. There was clinical and radiological progression of disease within 2 months of therapy. She began chemotherapy with pemetrexed-carboplatin.
In June 2017, she had new-onset pleural effusion. Alectinib 300 mg twice daily was started as third-line TKI. There was clinical benefit with no reported toxicity on subsequent follow-up. By RECIST criteria, she had partial response at 2 months which was sustained until December 2017. She presented after 6 months of therapy with alectinib with worsening cough and breathlessness. CECET scan confirmed radiological progression [ Figures 1-3 ]. Interestingly, she was never symptomatic for CNS disease despite failure of crizotinib and alectinib. She is presently planned for lorlatinib.
This case highlights the utility of second-generation TKI in ALK-positive NSCLC, especially in crizotinib refractory NSCLC. She tolerated crizotinib with sustained clinical benefit of 14 months. Ceritinib, her subsequent line of therapy, failed to control disease with progression within 2 months of initiation. With this background, alectinib has shown remarkable active in controlling an innately resistant disease for more than 6 months with no reported toxicity. Acquired mutations in ALK gene and P-glycoprotein overexpression have been reported mechanisms of crizotinib and certinib resistance which are overcome by alectinib. As our patient was unwilling for repeat biopsy, we were unable to identify resistant pathways which may help us choose from thirdgeneration TKI. [2] Two single-arm phase 2 studies (Shaw et al. and Ou et al.) [1, 3] evaluating alectinib in crizotinib-resistant disease showed PFS of 8.1 and 8.9 months and duration of response of 13·5 and 11.2 months, respectively. However, our patient had a PFS of only 6 months with alectinib.
In conclusion, sequential ALK suppression despite progression on TKI is the key to managing patients with ALK + NSCLC. Despite a shorter PFS than reported in literature, our patient had response to alectinib after two prior lines of ALK inhibitors. Future research should be directed at identifying mechanisms of resistance to ALK inhibitors which can help us choose the most appropriate TKI for our patients.
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There are no conflicts of interest. reported a 5-year OS rate of 76% for GC and 34% for non-GC types. These results were confirmed by several other studies. [8] In this study, we did not find any correlation with response rate and EFS on the basis of a cell of origin. This might be due to relatively small sample size and short follow-up.
Conclusion
The present study in northern Indian population shows key differences in the presentation as compared to the west, which include median age of 49 years (almost a decade and half less), higher male-to-female ratio, higher proportion of patients with poor ECOG performance status at diagnosis, higher proportion of patients with high and intermediate IPI risk group, more B symptoms, and extranodal disease. Lack of access to specialized cancer care centers, diagnostic delay, and suboptimal or inappropriate management compounded by socioeconomic factors are probably the factors attributing to the inferior outcome in this part of the world. The outcomes of DLBCL in India can be improved with the creation of regional cancer centers, structured data collection, centralized pathology review of histopathology, uniform chemotherapy protocols, appropriate training, and financial support.
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